2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer

      , ,
      Seminars in Cancer Biology
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="P1">Tumor angiogenesis and escape of immunosurveillance are two cancer hallmarks that are tightly linked and reciprocally regulated by paracrine signaling cues of cell constituents from both compartments. Formation and remodeling of new blood vessels in tumors is abnormal and facilitates immune evasion. In turn, immune cells in the tumor, specifically in context with an acidic and hypoxic environment, can promote neovascularization. Immunotherapy has emerged as a major therapeutic modality in cancer but is often hampered by the low influx of activated cytotoxic T-cells. On the other hand, anti-angiogenic therapy has been shown to transiently normalize the tumor vasculature and enhance infiltration of T lymphocytes, providing a rationale for a combination of these two therapeutic approaches to sustain and improve therapeutic efficacy in cancer. In this review, we discuss how the tumor vasculature facilitates an immunosuppressive phenotype and vice versa how innate and adaptive immune cells regulate angiogenesis during tumor progression. We further highlight recent results of antiangiogenic immunotherapies in experimental models and the clinic to evaluate the concept that targeting both the tumor vessels and immune cells increases the effectiveness in cancer patients. </p>

          Related collections

          Author and article information

          Journal
          Seminars in Cancer Biology
          Seminars in Cancer Biology
          Elsevier BV
          1044579X
          October 2018
          October 2018
          : 52
          : 107-116
          Article
          10.1016/j.semcancer.2018.06.002
          6548870
          29935312
          33c365f0-7aa1-4fb6-82a4-38c6ff7a704d
          © 2018

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article